WA’s Wheatbelt online news reports..
WA Upper House MP Brian Walker is in the spotlight over potential conflict of interests concerns after he was appointed ‘strategic consultant’ to an ASX-listed medicinal cannabis company.
Cannabiz reported Friday
Dr Brian Walker joins Creso Pharma as consultant and committee chair
Creso Pharma has appointed Legalise Cannabis WA MP Dr Brian Walker as a strategic consultant and chair of its new Scientific Advisory Committee.
The committee has been formed to expand the company’s pharmaceutical expertise and accelerate R&D, product development and clinical trials ahead of a potential NASDAQ listing
Dr Walker will oversee and provide input into Creso’s medicinal cannabis, hemp and psychedelic products.
He will work across all the firm’s divisions including wholly owned Canadian subsidiary Mernova, psychedelics arm Halucenex Life Sciences and its Swiss operation.
As well as his role as an MP, Dr Walker is a board member of Mind Medicines Australia, the industry body focused on expanding the options available to medical practitioners using psychedelic-assisted treatments.
Here’s the Creso Pharma press release via proactive
Creso Pharma appoints leading cannabis consultant to increase R&D capacity
Creso Pharma is evaluating near-term opportunities for expansion in the US and will leverage the extensive scientific industry expertise of Dr Walker and the Scientific Advisory Committee to unlock value for shareholders.
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has appointed Dr Brian Walker as a strategic consultant to increase its R&D and management capacity.
His appointment is expected to produce benefits across all CPH divisions including Swiss operations, Mernova Medicinal Inc. and Halucenex Life Sciences Inc
Dr Walker will also chair the newly created Scientific Advisory Committee and is a highly regarded politician and medical practitioner, with a long-standing commitment to cannabis legalisation and holistic wellness.
In 2021, Dr Walker was elected to the Western Australian Legislative Council as a Legalise Cannabis WA member for the East Metropolitan Region and is a board member of not-for-profit group, Mind Medicines Australia, the country’s peak body focused on expanding treatment options available to medical practitioners using psychedelic-assisted treatments.
Scientific Advisory Committee chair
Dr Walker’s appointment is the first of several Creso Pharma intends to make to the Scientific Advisory Committee board.
“We are very pleased to welcome Dr Brian Walker to Creso Pharma as a strategic advisor as well as the chair to our new Scientific Advisory Committee,” CPH non-executive chairman Adam Blumenthal said.
“Brian’s passion and knowledge on the scientific and pharmaceutical advantages of cannabis and hemp products will assist us in a number of efforts, including R&D, product development and access to a range of other specialists and industry leaders to round out the Committee.
“We look forward to additional committee appointments with both local and international specialists, particularly as we scale up our product offering and progress work towards clinical trials.”
The Scientific Advisory Committee and its board is expected to add to the growing body of evidence for Creso Pharma’s large portfolio of hemp-derived CBD, cannabis and psychedelic products.
What is the Scientific Advisory Committee?
CPH has formed the committee expand its pharmaceutical expertise in all applied science activities and believes the move will substantially increase the scope of work and fast track the current pipeline of product development and R&D initiatives.
The committee will also enable CPH to accelerate R&D, product development and other clinical trials ahead of its potential NASDAQ listing.
The Scientific Advisory Committee will add another level of oversight for CPH’s product development and highlights the scientific and evidence-based approach the company takes during the development of all medicinal cannabis, hemp-based and psychedelics products.
Creso Pharma is evaluating near-term opportunities for expansion in the US and will leverage the extensive scientific industry expertise of Dr Walker and the committee to unlock value for shareholders.
Dr Walker to drive growth
Dr Walker will oversee and provide input into CPH’s medicinal cannabis, hemp and psychedelic products and review and providing input on all the scientific documents related to the research and technical operations of CPH.
He will be instrumental in advising the board on new scientific developments and commercial opportunities that could support the success of Creso Pharma and evaluating potential R&D and scientific projects for CPH to participate in.
“I am honoured to be appointed as a consultant to Creso Pharma, and as the inaugural chair of the company’s Scientific Advisory Committee,” the Hon. Dr Brian Walker MLC said.
“Over the course of my career, I have always advocated for the use of medicinal cannabis and psychedelics as alternative treatments and this role will provide another avenue to broaden awareness of their benefits.
“Initially, my focus will be on appointing additional industry participants to join the committee, while pursuing potential trials, grants and opportunities which will highlight Creso Pharma’s leading products and potential in these growing subsectors of the medical field.”
Given his credentials, CPH is confident Dr Walker’s appointment will provide it with additional access to opportunities, including local and international peak bodies and industry participants and will leverage his established network to progress several near-term opportunities.